Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer
Status:
Terminated
Trial end date:
2019-04-20
Target enrollment:
Participant gender:
Summary
Letrozole is an aromatase inhibitor that is approved in the first-line treatment of
postmenopausal women with hormone receptor-positive or hormone receptor unknown locally
advanced or metastatic breast cancer. Sorafenib may stop the growth of tumor cells by
blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
This phase I/II trial is studying the side effects and best dose of sorafenib when given in
combination with letrozole and to see how well they work in treating postmenopausal women
with metastatic breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
Bayer National Cancer Institute (NCI) Novartis Pharmaceuticals Rutgers Cancer Institute of New Jersey